MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.61 5.01

Buy Sell

Overview

Share price change

24h

Current

Min

4.36

Max

4.67

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+76.14% upside

Dividends
By Dow Jones
Next Earnings	27 lut 2026

Market Stats
By TradingEconomics
Market Cap	59M 2.4B
Previous open	-0.4
Previous close	4.61

News Sentiment

By Acuity

50%

177 / 360 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 sty 2026, 23:49 UTC

Major Market Movers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 sty 2026, 21:12 UTC

Major Market Movers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 sty 2026, 20:29 UTC

Major Market Movers

Chip Makers Gain After Trump Calls Off European Tariffs

21 sty 2026, 20:04 UTC

Major Market Movers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 sty 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 sty 2026, 22:39 UTC

Earnings

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 sty 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 sty 2026, 21:19 UTC

Earnings

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 sty 2026, 20:45 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 sty 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 sty 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 sty 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 sty 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 sty 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 sty 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 sty 2026, 20:23 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 sty 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 sty 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 sty 2026, 20:08 UTC

Earnings

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 sty 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 sty 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 sty 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 sty 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 sty 2026, 19:24 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 sty 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 sty 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

76.14% upside

12 Months Forecast

Average 7.75 USD 76.14%

High 11 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

177 / 360 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.